Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.35 |
| ▸ | F2RL1 | P55085 | 3/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | ADK | P55263 | 1/20 | 0.30 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.30 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.30 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.30 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28747481 | 0.82 | ADRA2A (0.35) | ADRA2AADRA2BADRA2CMTORADK | |
| SCHEMBL2473033 | 0.81 | TAAR1 (0.40) | ADRA2AADRA2BADRA2CF2RL1ROCK1 | |
| SCHEMBL4363951 | 0.76 | MTOR (0.47) | ADRA2AADRA2BADRA2CMTORADK | |
| SCHEMBL1845506 | 0.75 | ADRA2A (0.59) | ADRA2AADRA2BADRA2CMTORADK | |
| SCHEMBL2469423 | 0.70 | FPR2 (0.42) | ADRA2AADRA2BADRA2CF2RL1 | |
| SCHEMBL2470670 | 0.70 | FPR2 (0.46) | ADRA2AADRA2BADRA2CROCK1 | |
| SCHEMBL6995795 | 0.70 | ALDH1A1 (0.40) | ADRA2AADRA2BADRA2CF2RL1MTOR | |
| SCHEMBL957222 | 0.70 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CROCK1 | |
| SCHEMBL2831573 | 0.68 | ALDH1A1 (0.39) | ADRA2AADRA2BADRA2CF2RL1MTOR | |
| SCHEMBL2472566 | 0.67 | FPR2 (0.43) | ADRA2AADRA2BADRA2CMTORADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546136-B1 | BENZOPYRAN DERIVATIVES SUBSTITUTED WITH SECONDARY AMINES INCLUDING IMIDAZOLE, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | KOREA RES INST CHEM TECH (KR) | 2011-10-05 | — | — | EP | disclosed |
| US-7279497-B2 | Benzopyran derivatives substituted with secondary amines including imidazole, their preparation and pharmaceutical compositions containing them | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2007-10-09 | — | — | US | disclosed |
| EP-1546136-A4 | BENZOPYRAN DERIVATIVES SUBSTITUTED WITH SECONDARY AMINES INCLUDING IMIDAZOLE, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | KOREA RES INST CHEM TECH (KR) | 2007-01-24 | — | — | EP | disclosed |
| US-20050267188-A1 | Therapy of cancer, rheumatoid arthritis, and diabetic retinopathies through anti-angiogenic properties, for protection of heart, neuronal cells, brain injury, organs for preservation or in cardiovascular surgery against ischemia-reperfusion injury or oxidative stress | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2005-12-01 | — | — | US | disclosed |
| EP-1546136-A1 | BENZOPYRAN DERIVATIVES SUBSTITUTED WITH SECONDARY AMINES INCLUDING IMIDAZOLE, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Korea Research Institute of Chemical Technology (KR) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004014898-A1 | BENZOPYRAN DERIVATIVES SUBSTITUTED WITH SECONDARY AMINES INCLUDING IMIDAZOLE, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267188-A1 | Therapy of cancer, rheumatoid arthritis, and diabetic retinopathies through anti-angiogenic properties, for protection of heart, neuronal cells, brain injury, organs for preservation or in cardiovascular surgery against ischemia-reperfusion injury or oxidative stress | FLT4, ALDH1A2, KDR | ADRA2A 1553/4885ADRA2B 1603/4885ADRA2C 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.